Skip to main content

HCP CH Utility menu

  • FOR CONSUMERS
  • CONTACT US
Bayer logo Miralax Logo

The information on this page is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL    I AM NOT A HEALTHCARE PROFESSIONAL

Home

HCP CH Main menu

  • About MiraLAX®
  • About Constipation
  • Studies & Guidelines
  • Patient Resources & Samples
Bayer Cross Logo

Start patients on MiraLAX® first: Its triple action hydrates, softens, and promotes gentle peristalsis1-3

 

Free Samples and Coupons

Miralax product bottle with benefits icons
purple doctor person icons - 9 dark purple and 1 light purple showing 9 out of 10 doctors

In a NEW survey of 300 GIs
9 in 10 said that MiraLAX® is the
OTC laxative they trust most5,a,b

aBased on a survey that asked 300 gastroenterologists to rate the important factors in choosing an OTC medication for adults with occasional constipation and how well MiraLAX® met those needs. HCPs selected from a set of options based on their clinical experience. Survey details and data are available upon request.5
bGIs rated the strength of their agreement with this statement ≥5 on a scale of 1-7.5

See the Results

purple doctor person icons - 9 dark purple and 1 light purple showing 9 out of 10 doctors

Your patients like these could benefit from starting MiraLAX® sooner

See Their Stories

MiraLAX®: One of the most rigorously studied OTC laxatives8

In a review spanning more than two decades of evidence, MiraLAX® received a stronger recommendation than stool softeners and fiber supplements

Watch to Learn More

MIRA-proven-datavis

MiraLAX® has a triple mechanism of action

MiraLAX® has a triple mechanism of action1-3

Efficacy proven in multiple clinical trials8‑12

Learn More
Patient Resources

Patient resources

Access downloadable tools to help support your patients.

Learn More

Click to expand.

    References

    References: 1. Schiller LR, Emmett M, Santa Ana CA, Fordtran JS. Osmotic effects of polyethylene glycol. Gastroenterology. 1988;94(4):933-941. doi:10.1016/0016-5085(88)90550-1 2. Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest. 1989;84(4):1056-1062. doi:10.1172/JCI114267 3. Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol. 2011;25(SupplB):16B-21B. 4. Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144(1):211-217. doi:10.1053/j.gastro.2012.10.029 5. Data on file, Bayer Healthcare. 6. US Food and Drug Administration. NDA 20-698. Approval letter for MiraLAX powder. February 18, 1999. 7. US Food and Drug Administration. NDA 22-015. Approval letter for MiraLAX powder OTC. October 6, 2006. 8. Rao SSC, Brenner DM. Efficacy and safety of over-the-counter therapies for chronic constipation: an updated systematic review. Am J Gastroenterol. 2021;116(6):1156-1181. doi:10.14309/ajg.0000000000001222 9. DiPalma JA, Cleveland MvB, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436-1441. doi:10.1111/j.1572-0241.2007.01199.x 10. Cleveland MvB, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J. 2001;94(5):478-481. 11. DiPalma JA, Cleveland MB, McGowan J, Herrera JL. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J. 2007;100(11):1085-1090. doi:10.1097/ SMJ.0b013e318157ec8f 12. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;(7):CD007570. doi:10.1002/14651858.CD007570.pub2

    MiraLAX HCP

    HCP Footer Center

    • Contact Us
      • Site Map
      • About MiraLAX®
      • About Constipation
    • Studies & Guidelines
      • Patient Resources & Samples

    ©2023. All rights reserved. Unless otherwise indicated, all trademarks are owned by Bayer, and its affiliates, or licensed for its use.

    USE AS DIRECTED

    Footer Bottom

    • Bayer Global
    • Bayer US
    • Bayer Consumer Health
    • Conditions of Use
    • Privacy Statement
    • Cookie Settings
    • Imprint
    • California Transparency in Supply Chains
    • Satisfaction Guarantee
    • AdChoices
    • Do not sell my personal data

    Level Access website accessibility icon